logo-loader
viewQ BioMed Inc.

Q BioMed extends clinical trial agreement with Washington University to study glaucoma drugs

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin and Mannin Research CEO George Nikopoulos tell Proactive on Wednesday the two companies announced that it is extending its option agreement with Washington University in St Louis to allow for further analysis of GDF-15 as a biomarker for monitoring glaucoma.

Nikopoulos says the independent studies will provide insights into the role of GDF-15 that will aid future clinical studies.

Quick facts: Q BioMed Inc.

Price: 1.6 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $35.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Q BioMed Inc awaits FDA approval of facility to manufacture 'revenue ready'...

Q BioMed Inc (OTC US:QBIO:) CEO Denis Corin tells Proactive Investors the commercial-stage biotechnology acceleration company is waiting for the US Food and Drug Administration to sign off on a new manufacturing facility to produce Strontium Chloride Sr89 injection. Corin says he is...

on 11/4/18

2 min read